Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2014 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial

CAMBRIDGE, Mass., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today...
August 28, 2014 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Baird 2014 Health Care Conference

CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today...
August 07, 2014 16:01 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2014 Financial Results

– Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia – – Management to host conference call today at 4:30 p.m. ET...
July 31, 2014 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Second Quarter 2014 Financial Results Webcast and Conference Call

CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today...